NovaVax News Flow Expected to Continue
Insights - It has been an eventful week for Novavax (NVAX), and we believe the news flow will spill over into next week. Biden’s Speech Included NovavaxOn … Continue Reading
Premium: Read NowInsights
Essa Dosing Cohorts Where Optimal Anti-tumor Effects Expected
Insights - Yesterday, Essa (EPIX) announced another collaboration, this time with Bayer. The two companies will run a combination of Essa’s EPI-7386 with Bayer’s Nubeqa (darolutamide) in patients with … Continue Reading
Premium: Read Now
Mono AFM24 Has Some Uncertainty, But Real Potential Is In NK Combo
Insights - Affimed had their business update call this morning to primarily discuss updates on AFM24 and a few other items. Below are notes. Licensed NK Cells from MD … Continue Reading
Premium: Read NowNotes from Affimed’s KOL Call Discussing AACR NK+AFM13
Insights - Affimed(AFMD) hosted a call after market today to discuss cbNK+AFM13 data presented at AACR. KOL from MD Anderson Dr. Katy Rezvani was also on the call. Below … Continue Reading
Premium: Read NowA Look At Essa & Jounce Preclinical Data at AACR ’21
Insights - A look at pre-clinical data that Jounce and Essa presented at AACR this past weekend. Jounce (JNCE)Jounce has breached the $10/share level with a weak … Continue Reading
Premium: Read NowAffimed’s AACR Data Validates Bi-Specifics In NK Cell Combinations
Insights - Affimed (AFMD) released initial clinical data from the AFM13 + MD Anderson combo study at AACR this morning and it looked great. Ultimately, this data validates AFMD … Continue Reading
Premium: Read Now
Expectations Ahead of AACR 2021
Insights - The American Association for Cancer Research (AACR) annual meeting will be hosted this coming weekend (April 9-14). Below is data to look for that will … Continue Reading
Premium: Read Now